Document:

WARRANT  NO.  003
                                 HUMATECH, INC.

                            WARRANT FOR THE PURCHASE
                            OF SHARES OF COMMON STOCK

November  16,  2001                                              500,000  Shares

     FOR  VALUE  RECEIVED,  Humatech,  Inc.,  an  Illinois  corporation  (the
"Company"),  hereby  certifies  that  David  Caney  or  other  holder  hereof
(collectively,  the  "Holder"),  is  entitled, subject to the provisions of this
Warrant,  to  purchase  from  the  Company,  at  any  time  or from time to time
beginning  five  business  days  after  the  date hereof, and ending at 5:00 pm,
central  time,  on  the  first  anniversary  of  the  date hereof (the "Exercise
Period")  Five Hundred Thousand (500,000) fully paid and nonassessable shares of
common  stock  of the Company, par value $.001 per share (the "Common Stock") at
the  exercise  price  of  One  Dollar  and  Fifty Cents (US$1.50) per share (the
"Exercise Price").  This Warrant is the Warrant described in and is being issued
pursuant  to  a  the  Consulting  Agreement  (the  "Agreement")  effective as of
November  16,  2001,  between  the  Company  and David Caney (the "Consultant").
Capitalized  terms  not defined in this Warrant shall have the meanings ascribed
to  them  in  the  Agreement.

     For  purposes  of this Warrant, "Warrant Shares" means the shares of Common
Stock  deliverable upon exercise of this Warrant, as adjusted from time to time.
Unless the context requires otherwise all references to Common Stock and Warrant
Shares  in this Warrant shall, in the event of an adjustment pursuant to Section
6  hereof,  be  deemed to refer also to any securities or property then issuable
upon  exercise  of  this  Warrant  as  a  result  of  such  adjustment.

     Section  1.     Exercise  of  Warrant.

     (a)  This  Warrant  may  be  exercised,  as a whole or in part, at any time
or  from  time  to time during the Exercise Period. The Holder may exercise this
Warrant  by telecopying an executed and completed Notice of Exercise in the form
annexed hereto as Exhibit A (a "Notice of Exercise") to the Company, and sending
the  original  by  overnight  delivery  service to the Company together with the
Exercise  Price.  Each  day  on  which a Notice of Exercise is telecopied to the
Company  in  accordance  with the provisions hereof shall be deemed an "Exercise
Date."  Notices  given  under  this  Warrant shall be delivered or telecopied as
follows:

   If  to  the  Holder:                   If  to  the  Company:

       David  Caney                           Humatech,  Inc.
                                              1718  Fry  Road,  Suite  450
                                              Houston,  Texas  77084
                                              Attention:  David  G.  Williams,
                                                          President
                                              Facsimile  No.  (281)  313-1254

or  to  such  other  address  as  the  Holder  may  specify.

     If  the Company has not delivered the Warrant Shares to the Holder prior to
the expiration of five business days after the Holder send a Notice of Exercise,
the,  in  addition  to all other remedies the Holder may have, the Company shall
pay  to  the Holder, on demand and in immediately available funds, as liquidated
damages  for  such  failure  and  not  as  a  penalty, the amounts stated in the
following  schedule, which liquidated damages shall begin to accrue on the sixth
business  day  after  the  Exercise  Date.

<PAGE>

                      Late  Payment  For  Each  $100,000
          No.  Business  Days  Late     of  the  Warrant  Exercise  Price
          -------------------------     ---------------------------------

                     1                           $100
                     2                           $200
                     3                           $300
                     4                           $400
                     5                           $500
                     >5                                   $500  +$200  for  each
                                                 business  day  late  beyond  5
                                                 days  from  the  Exercise  Date

     Nothing  in  this  Warrant  shall limit the holder's right to seek specific
performance  of  the  Company's  obligations  hereunder  and  other remedies and
damages for the Company's actions or inactions resulting in the transfer agent's
failure  to  issue  and  deliver  the Warrant Shares to the Holder.  The Company
shall  not be liable for any damages resulting from the transfer agent's failure
to  deliver  Warrant  Shares  to  the  Holder.

     (b)  The  Company  shall  pay  any  and  all  documentary  stamp or similar
issue  or  transfer  taxes  payable  in  respect of the issue or delivery of the
Warrant  Shares.

     (c)  Limitation  on  Right  and  Power  to  Exercise. Any provision in this
Warrant,  the  Agreement or any other document to the contrary not withstanding,
the Holder shall not have the right or power to exercise this warrant, either in
whole or in part, if, and any attempt to do so shall be void, after having given
effect  to  such  exercise,  the  Holder  shall  be or shall be deemed to be the
beneficial  owner of 10% or more of the then outstanding Common Stock within the
meaning  or  for  the  purposes of Section 13(d) or 13(g) of the U.S. Securities
Exchange  Act  of 1934, as amended, or as the term "beneficial owner" is defined
in  Rule  13d-3 of the U.S. Securities and Exchange Commission or otherwise. Any
attempt to exercise the Warrant shall also be ineffective to the extent that the
Company  does  not  have  sufficient  authorized, unissued and unreserved Common
Stock  to  issue  the  Warrant  Shares.

     Section  2.     Reservation  of  Shares.  The Company hereby agrees that at
all  times  there  shall  be reserved for issuance and delivery upon exercise of
this  Warrant  a sufficient number of shares of its Common Stock or other shares
of  capital  stock  of  the Company or other property from time to time issuable
upon  exercise  of  this Warrant.  All such shares shall be duly authorized and,
when  issued  upon  such  exercise in accordance with the terms of this Warrant,
shall  be  validly  issued,  fully paid and nonassessable, free and clear of all
liens,  security  interests,  charges  and other encumbrances or restrictions on
sale  (other  than  any  restrictions on sale pursuant to applicable federal and
state  securities  laws)  and  free  and  clear  of  all  preemptive  rights.

     Section  3.     Fractional  Shares.  The  Company  shall not be required to
issue fractional shares of Common Stock on the exercise of this Warrant.  If any
fraction  of  a  share  of Common Stock would, except for the provisions of this
Section  4,  be  issuable  on the exercise of this Warrant (or specified portion
thereof),  the  Company shall pay an amount in cash calculated by it to be equal
to  the  then  current market value per share of Common Stock multiplied by such
fraction  computed  to  the  nearest  whole  cent.

     Section  4.     Exchange,  Transfer,  Assignment  or  Loss  of  Warrant.

     (a)  This  Warrant  is  exchangeable, without expense, at the option of the
Holder, upon presentation and surrender hereof to the Company for other warrants
of  different  denomination,  entitling  the  Holder  thereof to purchase in the
aggregate  the  same  number  of  Warrant Shares and otherwise carrying the same
rights  as  this  Warrant.

     (b)  This  Warrant  may  be  divided  or  combined by the Holder with other
warrants  that  carry  the same rights upon presentation hereof at the office of
the  Company  together  with  a  written  notice  specifying  the  names  and
denominations  in  which  new warrants are to be issued and signed by the Holder
hereof.  The term "Warrant" as used herein includes any warrants into which this
Warrant  may  be  divided  or  for  which  it  may  be  exchanged.

<PAGE>

     (c)  Upon  receipt  by  the  Company  of evidence satisfactory to it of the
loss,  theft,  destruction  or  mutilation  of this Warrant, and (in the case of
loss, theft or destruction) of reasonably satisfactory indemnification, and upon
surrender  and  cancellation  of  this  Warrant, if mutilated, the Company shall
execute  and  deliver  a  new  Warrant  of  like  tenor  and  date.

     Section  5.     Intentionally  left  blank.

     Section  6.     Reclassification,  Reorganization, Consolidation or Merger.
In  the event of any reclassification, capital reorganization or other change of
outstanding  shares  of  Common  Stock  of  the  Company  or in the event of any
consolidation  or  merger of the Company with or into another corporation (other
than a merger in which merger the Company is the continuing corporation and that
does  not result in any reclassification, capital reorganization or other change
of  outstanding  shares  of  Common Stock of the class issuable upon exercise of
this  Warrant)  or  in  the  event of any sale, lease, transfer or conveyance to
another  corporation of the property and assets of the Company as an entirety or
substantially  as  an  entirety,  the Company shall, as a condition precedent to
such  transaction,  cause  effective  provisions  to  be made so that such other
corporation shall assume all of the obligations of the Company hereunder and the
Holder  shall have the right thereafter, by exercising this Warrant, to purchase
the  kind  and  amount  of  shares  of  stock  and other securities and property
(including  cash)  receivable upon such reclassification, capital reorganization
and  other change, consolidation, merger, sale, lease, transfer or conveyance by
a  holder  of the number of shares of Common Stock that might have been received
upon  exercise  of  this  Warrant  immediately  prior  to such reclassification,
capital  reorganization,  change,  consolidation,  merger,  sale,  lease  or
conveyance.  Any  such  provision  shall  include  provision  for adjustments in
respect  of such shares of stock and other securities and property that shall be
as  nearly  equivalent  as may be practicable to the adjustments provided for in
this  Warrant.  The foregoing provisions of this Section 6 shall similarly apply
to successive reclassification, capital reorganizations and changes of shares of
Common  Stock and to successive changes, consolidations, mergers, sales, leases,
transfers or conveyances.  In the event that in connection with any such capital
reorganization,  or  reclassification,  consolidation,  merger,  sale,  lease,
transfer  or  conveyance,  additional  shares of Common Stock shall be issued in
exchange,  conversion,  substitution  or payment, as a whole or in part, for, or
of,  a  security of the Company other than Common Stock, any such issue shall be
treated  as  an  issue  of  Common Stock covered by the provisions of Section 6.

     Section 7.      Transfer  to  Comply  with the Securities Act. Neither this
Warrant  nor  any  of  the  Warrant  Shares may be offered or sold in the United
States unless pursuant to an effective registration statement under the Act,  or
pursuant to other available exemptions from the registration requirements of the
Act. The Holder of this  Warrant or any of the Warrant Shares may not engage  in
hedging transaction with regard to such securities unless in compliance with the
Act.

     Section  8.     Availability of Information. So long as any of this Warrant
remains  unexercised  and this Warrant has not expired, the Company shall comply
with  the reporting requirements of Sections 13 and 15(d) of the Exchange Act to
the  extent  it  is required to do so under the Exchange Act, and shall likewise
comply  with  all  other applicable public information reporting requirements of
the  Securities  and  Exchange  Commission  (including  those  required  to make
available  the  benefits  of  Rule 144 under the Securities Act) to which it may
from  time  to time be subject. The Company shall also cooperate with the Holder
of  this  Warrant  and  the  Holder  of  any  Warrant  Shares  in supplying such
information  as  may  be  necessary  for  such  holder  to complete and file any
information reporting forms currently or hereafter required by the Commission as
a  condition  to  the  availability  of Rule 144 or any successor rule under the
Securities  Act  for  the  sale  of  this  Warrant  or  the  Warrant Shares. The
provisions  of this Section 7 shall survive termination of this Warrant, whether
upon  exercise  of  this  Warrant  in  full or otherwise. The Company shall also
provide  to  holders  of  this  Warrant the same information that it provides to
holders  of  its  Common  Stock.

     Section 9.      Successors and Assigns. All the provisions of this  Warrant
by or for the benefit of the Company or the  Holder  shall  bind  and  inure  to
the  benefit  of  their  respective  successors,  assigns,  heirs  and  personal
representatives.

<PAGE>

     Section  10.    Headings.  The headings  of  sections  of this Warrant have
been inserted for  convenience  of  reference  only, are not to be  considered a
part hereof  and  shall  in  no  way  modify  or  restrict  any  of the terms or
provisions hereof.

     Section  11.    Amendments.  This Warrant may  not be amended except by the
written  consent  of  the  Company  and  the  Holder.

     Section  12.    Notices.  All  notices  shall  be  as  set  forth  in  this
Agreement.

     Section  13.    Law Governing; Jurisdiction. This Warrant shall be governed
by and  construed  in  accordance  with the laws of the Texas. The courts of the
State of  Texas,  shall  have jurisdiction and venue for the adjudication of any
civil action between or among any of  them  arising  out  of  relating  to  this
Warrant. The Company and the Holder irrevocably consent to such jurisdiction and
venue, and irrevocably  waive  any  claim  of  forum  non conveniens or right to
change venue. The  prevailing  party  in  any action or proceeding to enforce or
construe this Warrant  is  entitled  to  recover  reasonable  attorney's  fees.

     Section  14.    Modification of Agreement.  The  Holder and the Company, by
supplemental agreement, may make any changes in this Warrant (i) that they shall
deem  appropriate  to  cure  any  ambiguity  or  to  correct  any  defective  or
inconsistent  provision  of  manifest mistake or error herein contained; or (ii)
that  they  may  deem necessary or desirable and that shall not adversely affect
the  interests  of  the  Holder  (this provision, for instance, shall permit the
Exercise  Price  to  be  decreased  or the Expiration Date extended).

     IN  WITNESS  WHEREOF,  the  Company  has  caused  this  Warrant  to be duly
executed,  as  of  November  16,  2001.

                                   HUMATECH,  INC.
                                   By
                                       _________________________________________
                                       David  G.  Williams,  President  and  CEO

                                   Date  Signed ________________________________

<PAGE>

                               NOTICE OF EXERCISE
To:  Humatech,  Inc.:

     The  undersigned  irrevocably  exercises  this  Warrant for the purchase of
____________________ shares (subject to adjustment) of Common Stock of Humatech,
Inc.  (the  "Company"):  for  this  Warrant  and  agrees  to  make  payment  of
$____________________  (the  "Exercise  Price")  through  the  following method:

     such  payment  of  the  Exercise  Price  being  in  cash or by certified or
     official  bank  check  payable  to  the  order  of  the  Company

all  at  the  Exercise  Price  and on the terms and conditions specified in this
Warrant,  and  directs  that  the  shares  of  Common Stock deliverable upon the
exercise  of this Warrant be registered or placed in the name and at the address
specified  below  and  delivered  thereto.

Date:  ________________,  _______

                                        ________________________________________
                                        (Signature  of  Owner)
                                        ________________________________________
                                        (Street  Address)
                                        ________________________________________
                                        (City) (State or Province) (Postal Code)
                                        ________________________________________
                                        (Country)

<PAGE>

Securities  and/or  check  to  be  issued  to:__________________________________

Name:___________________________________________________________________________

Street  Address:________________________________________________________________

City,  State  and  Zip  Code:___________________________________________________

Any unexercised part of the Warrant evidenced by the within Warrant to be issued
to:_____________________________________________________________________________

Name:___________________________________________________________________________

Street  Address:________________________________________________________________

City,  State  and  Zip  Code:___________________________________________________

<PAGE>

                               FORM OF ASSIGNMENT
     FOR  VALUE RECEIVED the undersigned registered holder of the within Warrant
hereby sells, assigns, and transfers unto the Assignee(s) named below (including
the  undersigned  with  respect  to  any  part of the Warrant not being assigned
hereby)  all  of  the  right  of  the undersigned under the within Warrant, with
respect  to  the  number  of  shares  of  Common  Stock  set  forth  below:

NAME OF ASSIGNEE   ADDRESS OF ASSIGNEE    SOCIAL SECURITY OR    NUMBER OF SHARES
                                          OTHER IDENTIFYING     OF COMMON STOCK
                                             NUMBER OF            ASSIGNED TO
                                             ASSIGNEE              ASSIGNEE

and does hereby irrevocably constitute and appoint ______________________ as the
undersigned's  attorney  to  make  such  transfer  on  the  books  of
______________________  Humatech,  Inc.  maintained  for that purpose, with full
power  of  substitution  in  the  premises.

Date:  ______________,  ____

                                           _____________________________________
                                           (Signature  of  Owner)
                                           _____________________________________
                                           (Street  Address)
                                           _____________________________________
                                           (City)     (State)        (Zip  Code)

1. The signature must correspond  with  the name as written upon the face of the
within  Warrant  in  every  particular, without alteration or enlargement or any
change  whatever.<PAGE>
                                                                   EXHIBIT 10.24

* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

                      MASTER LABORATORY SERVICES AGREEMENT

      This Master Laboratory Services Agreement ("Agreement"), when signed by
both parties, will set forth the terms and conditions between NORTHWEST
BIOTHERAPEUTICS, INC., a Delaware corporation with its principal offices located
at 21720 23rd Drive SE, Suite 100, Bothell, Washington 98021 ("Sponsor") and
QUINTILES LABORATORIES LIMITED, a North Carolina corporation with its principal
offices located at 5500 Highlands Parkway, Suite 600, Smyrna, Georgia 30082
("QLAB"), under which QLAB agrees to provide laboratory services to Sponsor as
set forth below.

Sponsor and QLAB agree as follows:

1.    SERVICES. QLAB shall provide study planning, consultation on laboratory
design, laboratory analysis, other laboratory services, and/or data management
services, as requested by Sponsor from time to time during the term of this
Agreement. The specific details of each assignment or task will be separately
negotiated and specified in writing on terms acceptable to the parties and
otherwise subject to the terms and conditions of this Agreement (each such
writing, a Confirmation of Central Laboratory Services ("CCLS")) in a document
substantially in the form of Appendix I to this Agreement.

2.    PAYMENT OF FEES AND EXPENSES.

      (a)   Each CCLS shall contain a provisional services budget ("PSB") for
the payment of QLAB's services to be performed pursuant to such CCLS as well as
additional terms and conditions related to the PSB. Sponsor will pay QLAB in
accordance with each PSB. Sponsor shall reimburse QLAB for all reasonable and
necessary travel, lodging and other expenses incurred in the performance of its
services that have been approved in writing by Sponsor.

      (b)   Upon execution of a CCLS, Sponsor shall pay QLAB an amount equal to
* of the applicable PSB as a project initiation payment. QLAB will draw from
these funds in order to pay for services and related costs and expenses
consistent with the terms of this Agreement.

      (c)   QLAB will invoice Sponsor monthly or as separately agreed for
services rendered under any CCLS and Sponsor shall pay all amounts due within
thirty (30) days of receipt of QLAB's itemized invoices for work completed. Each
invoice will reflect QLAB's application of any amounts advanced by Sponsor. If
any portion of an invoice is disputed, then Sponsor shall pay the undisputed
amounts within 30 days of receipt of the invoice, and the parties shall use good
faith efforts to reconcile the disputed amounts as soon as practicable.

      (d)   Overdue payments shall accrue interest at the rate of thirteen
percent (13%) per annum, and payments overdue for more than ninety (90) days
shall accrue interest at the rate of eighteen percent (18%) per annum, (or the
maximum lesser amount permitted by law) plus reasonable attorney's fees and
costs incurred by QLAB in connection with the collection thereof.

                                      -1-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

3.    TERM. This Agreement shall commence on the date of execution and shall
continue until terminated as hereinafter provided by either party.

4.    CONFIDENTIALITY.

      (a)   It is understood that during the term of this Agreement and each
CCLS, QLAB and its employees will be exposed to data and information, which is
confidential and proprietary to Sponsor. All such data and information ("Sponsor
Confidential Information") made available, disclosed or otherwise made known to
QLAB as a result of services under this Agreement or under any CCLS shall be
considered confidential and shall be considered the sole property of Sponsor.
All information regarding laboratory methods, laboratory pricing, and laboratory
management and all information regarding QLAB's operations, including but not
limited to QLAB Property (as defined in Section 5 below), disclosed by QLAB to
Sponsor in connection with this Agreement or any CCLS is proprietary,
confidential information belonging to QLAB (the "QLAB Confidential Information",
and together with the Sponsor Confidential Information, collectively referred to
as the "Confidential Information"). The Confidential Information shall be used
by the receiving party and its employees only for purposes of performing the
receiving party's obligations hereunder or under any CCLS. Each party agrees
that it will not reveal, publish or otherwise disclose the Confidential
Information of the other party to any third party without the prior written
consent of the disclosing party who may withhold such consent for any reason.

      (b)   The foregoing obligations shall not apply to Confidential
Information which:

            (i)   is or becomes generally available to the public other than as
                  a result of a disclosure by the receiving party;

            (ii)  becomes available to the receiving party on a non-confidential
                  basis from a source which is not prohibited from disclosing
                  such information by a legal, contractual or fiduciary
                  obligation to the disclosing party;

            (iii) the receiving party develops independently of any disclosure
                  by the disclosing party;

            (iv)  was in the receiving party's possession or known to the
                  receiving party prior to its receipt from the disclosing
                  party, as shown by contemporaneous written evidence; or

            (v)   is required by law to be disclosed.

      (c)   This obligation of confidentiality and non-disclosure shall remain
in effect for a period of ten years after the termination of this Agreement.

                                      -2-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

5.    PROPERTY OWNERSHIP.

      (a)   All data and information necessary for QLAB to conduct project
assignments will be forwarded by Sponsor to QLAB, and all such information
received from Sponsor shall remain the property of Sponsor.

      (b)   All data and information generated or derived by QLAB as the result
of services performed by QLAB under this Agreement shall be and remain the
exclusive property of Sponsor. Any inventions that may evolve from the data and
information described above or as the result of services performed by QLAB under
this Agreement ("Inventions") shall belong to Sponsor, and QLAB agrees to assign
all of its rights, title and interest in and to any Inventions and/or related
patents, effective upon their creation or conception to Sponsor. In addition,
QLAB:

            i.    shall assist Sponsor, at Sponsor's request and expense, during
                  and after the term of this Agreement, to evidence, transfer,
                  vest, perfect and enforce Sponsor's intellectual property
                  rights in the Inventions, and will execute any and all
                  instruments and perform all acts reasonably necessary or
                  desirable in order to establish, evidence, transfer, perfect,
                  enforce, vest or confirm in Sponsor the entire right, title
                  and interest in such Inventions, and also to execute any
                  instruments necessary or desirable in connection with any
                  continuations, renewals, or re-issues thereof or in the
                  conduct of any related proceedings, litigation or other
                  enforcement actions; provided that Sponsor's expenses
                  hereunder shall include reasonable compensation to QLAB for
                  its time spent in connection with enforcement actions or
                  proceedings; and

            ii.   shall promptly and fully disclose to Sponsor all Inventions
                  made, conceived or reduced to practice during the term of this
                  Agreement, and will promptly (in no event more than five
                  business days) deliver them to Sponsor upon request and in any
                  event upon the expiration or termination of this Agreement or
                  its term, other than termination due to Sponsor's material
                  breach of the Agreement; and

            iii.  agrees that all Inventions created as a result of services
                  performed under this Agreement are specifically ordered or
                  commissioned by Sponsor, and to the extent such Inventions
                  qualify as "works made for hire" under applicable copyright
                  law, they are hereby agreed to be "works made for hire." To
                  the extent such Inventions are not "works made for hire" under
                  applicable copyright law, QLAB agrees to assign (or cause to
                  be assigned) and does hereby assign fully to Sponsor the
                  exclusive ownership of the copyright in all such Inventions
                  and all rights comprised therein, along with ownership of and
                  title to all physical embodiments (in whatever media) of the
                  works, which shall vest in Sponsor as the works are fixed in
                  any tangible medium of expression.

                                       -3-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

      (c)   Notwithstanding the foregoing, Sponsor acknowledges that QLAB
possesses certain inventions, processes, know-how, trade secrets, improvements,
other intellectual properties and other assets, including but not limited to
laboratory analyses, analytical and laboratory methods, processes, approaches,
procedures and techniques, technical expertise and conceptual expertise in area
of laboratory services, procedure manuals, personnel data, financial
information, computer technical expertise, and software, which have been
independently developed by QLAB and which relate to its business or operations
(collectively "QLAB Property"). Sponsor and QLAB agree that any QLAB Property or
improvements thereto which are used, improved, modified or developed by QLAB
under or during the term of this Agreement or any CCLS are the sole and
exclusive property of QLAB.

      (d)   At the completion of the services by QLAB, all materials and other
data owned by Sponsor shall either be: (i) delivered to Sponsor in such form as
is then currently in the possession of QLAB, subject to the payment obligations
set forth in Section 2 herein; (ii) retained by QLAB for Sponsor for a period of
two (2) years; or, (iii) disposed of, at the direction and written request of
Sponsor. Sponsor shall pay the costs associated with any of the above options.
Each party, however, reserves the right to retain, at its own cost and subject
to the confidentiality provisions herein, one copy of all documents and
materials relating to the services, to be used solely to satisfy regulatory
requirements or to resolve disputes regarding the services.

6.    REGULATORY COMPLIANCE; INSPECTIONS.

      (a)   In carrying out its responsibilities under this Agreement and each
CCLS, QLAB agrees to conduct its services in compliance with all applicable
laws, rules and regulations, including but not limited to the U.S. Food, Drug
and Cosmetic Act and the regulations promulgated pursuant thereto, and with the
standard of care customary in the central laboratory industry.

      (b)   Sponsor warrants that neither any assignment or task requested by
Sponsor nor the conduct thereof as provided in this Agreement or in any CCLS
shall violate any applicable law or regulation. Sponsor shall notify QLAB
promptly in writing of any FDA or other governmental inspection or inquiry
concerning any services that have been rendered or are being rendered by QLAB,
or any study or project to which such services relate.

      (c)   Neither QLAB nor any of QLAB's employees rendering services pursuant
to this Agreement has been debarred pursuant to Section 306 of the Federal Food,
Drug, and Cosmetic Act, as amended, and QLAB will not knowingly employ any
person or entity that has been so debarred to perform services under this
Agreement or any CCLS. QLAB shall notify Sponsor immediately upon the
commencement of any such proceeding concerning QLAB or any such employee.

      (d)   If any governmental or regulatory authority conducts or gives notice
to QLAB of its intent to conduct an inspection at QLAB's facilities or take any
other regulatory action with respect to any study or services provided under
this Agreement, QLAB will promptly give Sponsor notice

                                      -4-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

thereof, including all information pertinent thereto, and, where reasonably
practicable, QLAB will notify Sponsor prior to complying with such a demand or
request. Sponsor, however, acknowledges that it may not direct the manner in
which QLAB fulfills its obligations to permit inspection by governmental
entities.

      (e)   During the term of this Agreement and each CCLS, QLAB will permit
Sponsor's representative(s) (unless such representatives are competitors of
QLAB) to examine the work performed hereunder and the specific facilities at
which the work is conducted during regular business hours upon reasonable
advance notice and in a reasonable manner to determine that the project
assignment is being conducted in accordance with the applicable CCLS and that
the facilities are adequate; provided, however, that all information, other than
Sponsor Confidential Information, disclosed or revealed to or ascertained by
Sponsor in connection with any such examination shall be deemed to constitute
QLAB Confidential Information for purposes of this Agreement. Unless the costs
of governmental audits related to this Agreement or CCLS or Sponsor audits are
specifically included in the PSB, Sponsor shall reimburse QLAB for its time and
expenses associated with such audits and investigations.

7.    CONFLICT OF AGREEMENTS. QLAB represents to Sponsor that QLAB is not a
party to any agreement which would prevent QLAB from fulfilling its obligations
under this Agreement, and that during the term of this Agreement, QLAB will not
enter into an agreement to provide services which would prevent QLAB from
providing the services contemplated to be provided by QLAB under this Agreement
or any CCLS.

8.    INDEMNIFICATION.

      (a)   Sponsor shall defend, indemnify and hold harmless QLAB, its
affiliates and its and their respective directors, officers, employees and
agents (each, an "Indemnified Party") from and against any and all losses,
claims, actions, damages, liabilities, costs and expenses, (including reasonable
attorney's fees and court costs) (collectively, "Losses"), joint or several,
resulting or arising from any third-party claims, actions, proceedings,
investigations or litigation relating to or arising from or in connection with
this Agreement or any CCLS or the services contemplated herein (including,
without limitation, any Losses arising from or in connection with any study,
test, product or potential product to which this Agreement or any CCLS relates),
except to the extent such Losses are determined to have resulted solely from
negligence or intentional misconduct of the Indemnified Party seeking indemnity
hereunder.

      (b)   QLAB shall: (i) give Sponsor prompt notice of any such claim or law
suit (including a copy thereof served upon QLAB); (ii) cooperate with Sponsor
and its legal representatives in the investigation of any matter the subject of
indemnification, and (iii) not unreasonably withhold its approval of the
settlement of any such claim, liability or action by Sponsor that is the subject
of this Indemnification provision.

                                      -5-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

      (c)   Subject to Section 9 below, QLAB will defend, indemnify and hold
Sponsor harmless from and against all Losses arising from any breach of QLAB's
warranties, covenants or obligations under this Agreement or otherwise arising
out of or in connection with QLAB's negligent acts or negligent omissions.
Amounts finally determined to be owing under this paragraph may be deducted from
any payments owed by Sponsor to QLAB under this Agreement.

9.    LIMITATION OF LIABILITY. Neither QLAB nor its affiliates nor any of its or
their respective directors, officers, employees or agents shall have any
liability of any type (including, but not limited to, contract, negligence and
tort liability) for any special, incidental, indirect or consequential damages,
including, but not limited to the loss of opportunity, loss of use, or loss of
revenue or profit in connection with or arising out of this Agreement, any CCLS,
or the services performed by QLAB hereunder, even if such damages may have been
foreseeable to QLAB. In addition, in no event shall the collective, aggregate
liability of QLAB and its affiliates and its and their respective directors,
officers, employees and agents under this Agreement or any CCLS exceed the
amount of fees actually received by QLAB from Sponsor pursuant to this Agreement
for the assignment or task from which such liability arose.

10.   DISCLOSURE OF HAZARDS. Sponsor shall provide QLAB with all information
available to it regarding known or potential hazards associated with the use of
any substances supplied to QLAB by Sponsor and Sponsor shall comply with all
current legislation and regulations concerning the shipment of substances by
land, sea or air.

11.   PUBLICATION. Project results may not be published or referred to, in whole
or in part, without the prior written consent of Sponsor. Neither party may use
the other party's name in connection with any publication or promotion without
the other party's prior, written consent, which consent will not unreasonably be
delayed or withheld.

12.   TERMINATION.

      (a)   This Agreement or any CCLS may be terminated with or without cause
by Sponsor or by QLAB at any time during the term of this Agreement on ninety
(90) days prior written notice to QLAB or Sponsor, as appropriate.

      (b)   Either party may terminate this Agreement or any CCLS for material
breach upon thirty (30) days written notice specifying the nature of the breach,
if such breach has not been substantially cured within the thirty (30) day
period. In the event that QLAB in good faith, reasonably determines, in its sole
discretion, that its continued performance of the services contemplated by a
CCLS would constitute a potential or actual violation of regulatory or
scientific standards of integrity, QLAB may terminate this Agreement or the
applicable CCLS by giving written notice stating the effective date (which may
be less than thirty days from the notice date) of such termination.

                                      -6-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

      (c)   Termination of this Agreement shall constitute termination of all
CCLS's hereunder. Termination of a CCLS shall constitute a termination of such
CCLS only and shall not affect this Agreement or any other CCLSs outstanding
hereunder. Any written termination notice shall identify each specific CCLS that
is being terminated.

      (d)   In the event this Agreement is terminated, Sponsor shall pay to
QLAB: (i) any fees for services rendered then due and owing to QLAB because of
any performance of QLAB's obligations hereunder and all expenses reasonably
incurred in performing those services; (ii) all actual costs (including time
spent by QLAB personnel, which shall be billed at QLAB standard rates) to
complete activities associated with the termination and close out of projects;
and (iii) all kit destruction costs as noted in each CCLS. If payments in a
terminated CCLS are milestone-based, but that milestone has not yet been
completed, Sponsor will pay QLAB's standard fees for actual work performed
toward that milestone up to the date of termination. Upon the termination of
this Agreement, QLAB shall deliver to Sponsor all data and materials provided by
Sponsor to QLAB for the conduct of services under this Agreement.

      (e)   Termination of this Agreement or any CCLS hereunder shall not
constitute a release or waiver of any right or remedy available to either party
in connection herewith or therewith.

13.   INDEPENDENT CONTRACTOR RELATIONSHIP. Notwithstanding any provision herein
to the contrary, the parties hereto are independent contractors, and nothing
contained in this Agreement or in any CCLS shall be construed to place them in
the relationship of partners, principal and agent, employer and employee, or
joint venturers. Each party agrees that it shall have no power or right to bind
or obligate the other, and neither party shall hold itself out as having such
authority.

14.   INSURANCE. Each Party shall have and maintain such types and amounts of
liability insurance as is normal and customary in the industry generally for
parties similarly situated, and shall upon request provide the other Party with
a copy of its policies of insurance in that regard, along with any amendments
and revisions hereto.

15.   FORCE MAJEURE AND RELATED MATTERS. QLAB shall not be liable or responsible
to Sponsor nor be deemed to have defaulted under or breached this Agreement or
any CCLS for or in respect of errors, delays or other consequences arising from
Sponsor's failure to provide documents, materials, information or cooperation
required by QLAB in order to perform properly and timely QLAB's obligations
hereunder or thereunder. Sponsor acknowledges that, if it materially delays or
suspends performance of the services, then the personnel and/or resources
originally allocated to the project may be re-allocated, and QLAB will not be
responsible for delays due to required re-staffing or re-allocation of
resources. Any delay or hindrance in the performance of any of the duties or
obligations of either party hereto (except the payment of money owed) shall not
be considered a breach of this Agreement and the time required for performance
shall be extended for a period equal to the period of such delay, provided that
such delay has been caused by or is the result of any labor

                                      -7-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

disputes, including strikes, lockouts, job actions or boycotts; inability to
procure materials or services; riots; insurrection; embargoes; war; acts of God;
acts of the public enemy; inclement weather; fires; explosions; floods or other
natural disasters; or other reasons or causes beyond the reasonable control of
the party seeking to perform.

16.   NOTICES AND DELIVERIES. Any notice required or permitted to be given by
either party hereunder shall be in writing and shall be deemed given on the date
received if delivered personally or by nationally recognized overnight delivery
service or three days after the date postmarked if sent by registered or
certified U.S. mail, return receipt requested, postage prepaid to the following
addresses:

      If to QLAB:                   Quintiles Laboratories Limited
                                    5500 Highlands Parkway, Suite 600
                                    Smyrna, Georgia 30082
                                    Attn: S. Tim Derrington
                                          Chief Operating Officer

      If to Sponsor:                Northwest Biotherapeutics, Inc.
                                    21720 23rd Drive SE, Suite 100
                                    Bothell, WA 98021
                                    Attn:  Director of Clinical Operations

The expense and risk of loss for all deliveries, shipments, and mailings shall
be born by Sponsor. QLAB disclaims any liability for loss or damage occurring
during shipment, delivery or mailing, except to the extent that such loss or
damage is caused by the negligence or intentional misconduct of QLAB.

17.   MISCELLANEOUS.

      (a)   GOVERNING LAW. This Agreement and each CCLS shall be construed,
interpreted in accordance with and enforced under the laws of the State of
Washington, without regard to the conflict of laws provisions thereof. If any
one or more provisions of this Agreement or any CCLS shall be found to be
illegal or unenforceable in any respect, it is the intent of the parties that
such provisions be replaced, reformed or narrowed so that their original
business purpose can be accomplished to the extent permitted by law, the
validity, legality and enforceability of the remaining provisions shall not in
any way be affected or impaired thereby.

      (b)   SURVIVAL. The obligations of the parties contained in Sections 4, 5,
6, 8, 9 and 11 shall survive the termination of this Agreement.

      (c)   ENTIRE AGREEMENT; AMENDMENTS. This Agreement, together with each
CCLS, contains the entire understanding of the parties with respect to the
subject matter herein, and

                                      -8-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

supersedes all previous agreements (oral and written), negotiations and
discussions. The parties may modify or amend the provisions hereof only by an
instrument in writing duly executed by the parties.

      (d)   BINDING AGREEMENTS AND ASSIGNMENT. This Agreement shall be binding
upon and inure to the benefit of Sponsor and QLAB and their respective
successors and permitted assigns. Neither this Agreement nor any of either
party's rights hereunder may be assigned or otherwise transferred by either
party without the prior written consent of the other.

      (e)   WAIVER. No waiver by either party of any breach of any provision of
this Agreement or any CCLS shall constitute a waiver of any other or subsequent
breach.

      (f)   HEADINGS. The descriptive headings of the sections of this Agreement
are inserted for convenience only and shall not control or affect the meaning or
construction of any provision hereof.

      (g)   INCORPORATION BY REFERENCE. All exhibits attached hereto shall be
deemed to be incorporated herein. In case of any conflict between this Agreement
and any such attachment or any CCLS, the terms of this Agreement shall prevail
over the attachment or CCLS.

      (h)   For all CCLS's in which QLAB will earn fees or incur expenses in
excess of one million U.S. Dollars in a currency differing from the invoice and
payment currency, a foreign currency exchange provision will be included in the
CCLS.

      (i)   Any controversy or claim arising out of or relating to this
Agreement or the breach thereof shall be settled by arbitration administered by
the American Arbitration Association ("AAA") under its Commercial Arbitration
Rules, and judgment on the award rendered by the arbitrator shall be binding and
may be entered in any court having jurisdiction thereof. Such arbitration shall
be filed and conducted at the office of the AAA closest to QLAB if initiated by
Sponsor or, nearest to Sponsor if initiated by QLAB, and shall be conducted in
English by one arbitrator mutually acceptable to the parties selected in
accordance with AAA Rules.

      IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto
through their duly authorized officers and is effective as of the last date set
forth below.

QUINTILES LABORATORIES LIMITED            NORTHWEST BIOTHERAPEUTICS, INC.

By: /s/ S. TIM DERRINGTON                 By: /s/ DANIEL O. WILDS
   ------------------------------------      -----------------------------------
       S. Tim Derrington                            Daniel O. Wilds

Title: Chief Operating Officer               Title: Chairman, President and CEO
       Quintiles Laboratories Worldwide

Date: November 14, 2001                      Date: November 21, 2001

                                      -9-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

                                  APPENDIX I-1

                                 CONFIRMATION OF
                           CENTRAL LABORATORY SERVICES

                         NORTHWEST BIOTHERAPEUTICS, INC.

                                PROTOCOL DC3-HRPC

                                NOVEMBER 14, 2001

                                      -10-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

This Confirmation of Central Laboratory Services specifies the terms and
conditions upon which Quintiles Laboratories ("QLAB") will provide analytical
and data management services for the clinical trial described herein. QLAB, or
its agents, make no other commitments or warranties, either expressed or
implied, concerning the scope of services to be provided during the course of
this agreement. The Sponsor and its agents recognize and affirm that the
liability for any breach by QLAB shall be limited to the amount of fees paid to
QLAB by Northwest Biotherapeutics, Inc. or its agents before and during the
course of Northwest Biotherapeutics, Inc. Protocol DC3-HRPC.

PROTOCOL IMPLEMENTATION AND SUPPORT

A.1   Projected Time Period and Scope of Services

<TABLE>
<S>                                                   <C>
Confirmation of Central Laboratory Services Date:     November 14, 2001

Protocol Number:                                      DC3-HRPC

Project Initiation:                                   September 2001

Investigator Sites:                                   25 - United States

Enrolled Patients:                                    495

Average Patients per Site:                            19-20
</TABLE>

A.2   Protocol Specific Scope of Work

QLAB, in conjunction with The Sponsor, will complete a protocol specific Scope
of Work. The Scope of Work will define all of the protocol and procedural
parameters necessary for database construction kit specification & design,
customized requisitions & reports, and the investigator instruction manual.

A.3   Visit Specific Kits

QLAB will provide to each investigator site all materials necessary for
collection and transport of specimens to be tested at QLAB in accordance with
industry standards. These materials will include visit-specific laboratory
requisitions and kits designed to meet the needs of this clinical trial. All
laboratory requisitions, collection materials and mailers will be pre-labeled
with a unique bar-coded accession number. The accession number will be used
throughout the study to ensure accurate tracking, collation, and reporting of
patient laboratory data.

                                      -11-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

A.4   Investigator Training

QLAB will provide a protocol-specific instruction manual to each investigator
and training to the study coordinators in all laboratory procedures and services
pertaining to this clinical trial at the Investigator meeting. Items to be
covered will include, but will not be necessarily limited to, proper specimen
collection and processing, on-site archival of frozen specimens, and shipping of
samples under conditions to maximize analyte stability. The Sponsor or its
designated representative will provide QLAB with investigator telephone,
facsimile and site number. QLAB will send site verification forms to check
delivery addresses for supplies and laboratory reports as well as 24-hour, 7-day
telephone numbers for communication of telephone and panic alert test results.
QLAB will be eligible for reimbursement of all production and distribution costs
of investigator meeting materials as well as any reasonable travel-related
expenses incurred therein. All Materials will be printed in English. Documents
printed in languages other than English will result in additional fees.

A.5   Expedited Specimen Transport

QLAB will be responsible for arranging for express shipping with a courier who
provides a system by which clinical trial specimens can be tracked during
shipment. The risk of loss during shipment, however, shall be born by The
Sponsor, and Quintiles disclaims any liability for loss or damage occurring
during shipment, except to the extent that such loss or damage is caused by the
negligence or intentional misconduct of QLAB.

In the continental United States, ambient specimens can be shipped Monday
through Saturday on the day of collection. Ambient specimen shipments from sites
in Canada will be limited to Monday through Friday on the day of collection,
with the exception of remote locations. Ambient specimen shipments from sites in
Alaska and Hawaii will be limited to Monday through Thursday on the day of
collection. Frozen shipments from sites in the continental United States and
Canada will be limited to Monday through Thursday, and Monday through Wednesday
for sites in Alaska and Hawaii.

A.6   Ancillary Shipping Procedures

Sunday or holiday shipments may result in fees in excess of the visit fee.
Ancillary shipping fees will be subject to prior approval by The Sponsor unless
QLAB's Laboratory Director deems it necessary to act immediately in order to
ensure that specimens are received within the established limits of analyte
stability.

A.7   Dry Ice Services

QLAB does not provide dry ice services. However, QLAB can assist in the
coordination of dry ice services in certain regions on an optional basis only.

                                      -12-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

A.8   Patient Identification

From customized visit specific laboratory requisitions, QLAB will collect and
report patient demographic data as required by The Sponsor's protocols and
procedures and based on QLAB's capabilities.

DATA GENERATION AND TRANSMITTAL

B.1   Laboratory Data Reporting

Laboratory reports of test results will be sent to the investigators via
facsimile on the day testing is completed, followed by weekly hard copy reports.
Laboratory report formats will be determined during the protocol planning and
implementation phase.

B.2   Notification of Alerts

QLAB will contact investigators as defined in the Scope of Work with Telephone
High, Telephone Low, Panic High, Panic Low and Exclusion Alerts. QLAB will
contact The Sponsor or its designated representative with Panic Highs and Lows
and for all flags if the investigator cannot be reached.

B.3   Blinding

Blinding of selected laboratory results is available as an optional service from
QLAB. If The Sponsor determines that there is a requirement for blinding of
results in this clinical trial, such requirements will be defined in the Scope
of Work.

B.4   Electronic Data Transmission

QLAB will transfer clinical trial data in a pre-determined format, media and
schedule directly from our facility to The Sponsor's data management facility or
designated representative location.

B.5   Status Report

QLAB will provide The Sponsor or its designated representative with status
reports throughout the conduct of this trial summarizing the number of patients
tested to date by visit for each investigator site. The frequency and mode of
distribution of the status report are defined in the Scope of Work.

B.6   Data Retention

QLAB will maintain on-line all laboratory data compiled from this clinical trial
for the term of the clinical trial plus 18 months. Thereafter, all laboratory
data will be archived onto compact disc

                                      -13-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

media for a period of ten years. At the end of that ten-year period, QLAB will
forward electronic records to The Sponsor or retain for an additional fee,
according to The Sponsor's written instructions.

B.7   Confidentiality

QLAB will maintain the confidentiality of information related to the conduct and
results of this clinical trial as outlined in QLAB's internal policies, or under
the provisions of a Confidentiality Agreement to be executed with The Sponsor,
or under the provisions of any Master Services Agreement or Master Laboratory
Services Agreement that applies to this Confirmation of Laboratory Services.

B.8   QNET Software Product

If Sponsor requests the use of QNET in the Scope of Work, QLAB will provide
Sponsor or its designated party with the services of the QNET software product
according to the terms and conditions of the QNET SOFTWARE LICENSE AGREEMENT
agreed to under separate signature of both QLAB and Sponsor. QLAB will be
eligible for reimbursement of all pre-approved travel-related expenses incurred
with the installation of QNET at the Sponsor designated location(s) as well as
pre-approved travel-related expenses incurred as part of any required QNET
support.

ANALYTICAL SERVICES

C.1   Laboratory Events Schedule

The schedule for analytical and related laboratory services for The Sponsor's
Protocol DC3-HRPC is outlined as Exhibit A.

C.2   Test Groups

Analytical services referenced in the Laboratory Events Schedule for Protocol
DC3-HRPC are outlined as Exhibit B.

C.3   Analytical Standards and Certification

QLAB will maintain all state and federal licenses required to perform diagnostic
testing on interstate specimens. QLAB documents all in-house quality control and
quality assurance programs and will make available applicable results from
inter-laboratory proficiency programs conducted by the College of American
Pathologists or similar accrediting organizations during central laboratory
audits (see section C.16 Central Laboratory Audits).

                                      -14-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

C.4   Analytical Methodology Comparability

In order to provide consistency of results throughout the clinical trial
program, QLAB will maintain the same test methodology and procedures utilized
for the first laboratory-testing visit. The Sponsor may elect to adopt new and
improved technology or revised procedures whenever QLAB makes them available.
The Sponsor recognizes that circumstances beyond the control of QLAB can arise
which would preclude the use of the same testing methodology throughout the
clinical trial. Should this situation arise, QLAB will confer with The Sponsor
prior to the selection of an alternative methodology.

C.5   Specimen Stability

Analytical services will not be performed on specimens for which the elapsed
time from collection to analysis exceeds established limits of analyte
stability. QLAB also reserves the right to cancel testing on specimens whose
physical or chemical condition may jeopardize result integrity.

C.6   Test Priority Specified by Sponsor

Testing of quantity not sufficient (QNS) specimens can be performed in a
pre-determined and prioritized order established by The Sponsor. All QNS testing
will be conducted within the limits of QLAB's analytical capabilities.

C.7   Reference Ranges and Reporting Units

Reference ranges and units will be those established by QLAB's Quality Assurance
Group as those, which are appropriate and available for the test methodologies
being used in this clinical trial. QLAB reserves the right to periodically amend
reference ranges as changes in instrumentation, reagent formulation,
international standards, governmental recommendations, and testing methodologies
are adopted throughout the clinical laboratory industry. However, no changes
will be implemented without the explicit knowledge and consent of The Sponsor.

C.8   Exclusion Criteria

One exclusion value for each analyte and at specified visits may be selected by
The Sponsor. All test results for a given analyte will be compared to this
value. Results will be flagged as EX on the QLAB laboratory report.

C.9   High and Low Flags

Test results will be compared to sex stratified ranges and will be flagged as
High or Low if the result violates the established range.

                                      -15-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

C.10  Telephone Alert and Panic Alert Values

Telephone and Panic Alert values will be those levels selected by the Sponsor
where such levels are appropriate and available from QLAB. QLAB reserves the
right to not implement a Panic Alert level that is inconsistent with generally
accepted clinical laboratory standards. QLAB's Laboratory Director will discuss
the setting of Panic Alert levels with the Sponsor as appropriate.

C.11  Delta Flags

Delta flags will be reported for those patients whose laboratory values differ
by a specified percentage relative to the laboratory visit established by The
Sponsor as the baseline. Delta changes will be reported as +D or -D if the
checked value has increased or decreased relative to the reference visit.

C.12  Specimen Retention

All specimens will be retained for a period of up to 7 days after reporting and
will be made available for repeat testing if the elapsed time since specimen
collection falls within the established limits of stability. Repeat testing will
be performed at no additional charge if it is required due to the negligent acts
or omissions of QLAB.

C.13  Specimen Management

QLAB will be responsible for monitoring and maintaining the temperature and
other environmental conditions for frozen specimens which are being stored for
an interim period prior to batch testing or shipping to another analysis
facility. Storage times and conditions will be specified by The Sponsor in
advance of the clinical trial commencement.

C.14  Specimen Storage

Long term specimen storage is a standard service offering of QLAB. Long term
storage is defined as being a period greater than seven (7) days. If The Sponsor
requests this service from QLAB, additional fees will be included in the
Provisional Services Budget.

C.15  Central Laboratory Auditing

The Sponsor shall have the ability, upon reasonable notice to QLAB, to visit
QLAB and examine all systems, documents and other materials related to the
study. If The Sponsor audits QLAB, the parties shall cooperate and work in good
faith to resolve any unsatisfactory audit findings. In addition, QLAB shall
reasonably cooperate with and shall allow the Food and Drug Administration (FDA)
and other governmental agencies to visit QLAB and to examine all systems,
documents and other materials related to the study.

                                      -16-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

FEES AND BILLING

D.1   Scheduled Visit Fees

Scheduled visit fees which include analytical testing by visit and reporting
along with database configuration, maintenance and transfer, project management,
and transportation costs are included in Exhibit C.

D.2   Kit Construction Fees

Kit construction fees which include the cost of visit specific collection kits
and materials, as well as shippers, are included in the Provisional Services
Budget. Sponsor will be invoiced for these costs at the time they are shipped to
the investigator sites.

D.3   Transportation Fees

All transportation fees in the Provisional Services Budget are estimates.
Transportation will be handled as a direct pass through cost to The Sponsor on
the monthly invoice. Quintiles Laboratories applies a kit transportation
management fee to each kit for the administrative cost of managing the
transportation of supplies to the sites and the movement of samples to QLAB
and/or a sponsor designated location.

D.4   Unscheduled Visit Fees and Optional Test Fees

The fee for Services rendered by Quintiles Laboratories which relate to
unscheduled visits is set forth in Exhibit C and shall be paid in accordance
with the terms set forth therein. Any visits not listed in Exhibit C are
considered unscheduled visits, fees for which are to be paid pursuant to the
terms of Exhibit C. Unscheduled visit fees are not included in the Provisional
Services Budget and, therefore, are not subject to the Initiation Fee.
Unscheduled visit fees will be invoiced during the course of the study when they
occur. Fees for optional tests are set forth in the Provisional Services Budget
and relate to laboratory procedures required by the Protocol but performed only
on selected patients under certain conditions, and will be invoiced as
appropriate during the course of the study. (EXAMPLE: OPTIONAL TEST - SERUM
PREGNANCY).

D.5   Expenses

QLAB shall be reimbursed by The Sponsor for all-reasonable and necessary travel
and lodging expenses incurred in the performance of services provided herein
which have been pre-approved by The Sponsor. Additionally, investigator site
special requests for supplies that are not included in the bulk supply kit or
other special requests shall be approved by and reimbursed by The Sponsor.
Payment for such services shall be made to QLAB within thirty (30) days of
receipt by The Sponsor

                                      -17-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

of invoices or other evidence of such expenditures. Sponsor/CRO provided
investigator information (name, address, phone and fax number) will be used when
shipping study collection materials to investigators, as well as the
construction of investigator data base information. If the Sponsor/CRO provided
investigator information is incorrect and QLAB is assessed a transportation
penalty fee for non-deliverable packages, QLAB will invoice The Sponsor for
assessed penalty fees plus a database change fee of $ * .

D.6   Terms of Project Initiation Invoicing

After award of the project by The Sponsor, QLAB will invoice a project
initiation fee of * of the value of the estimated Provisional Services Budget.
The initiation fee will be credited back to The Sponsor against the final
invoice for the project.

D.7   Invoices and Billing

Laboratory services will be invoiced based on the receipt of specimens. An
invoice for all visit specific specimens received during the month plus any
expenses incurred will be issued to The Sponsor the following month. If
requested, QLAB can provide a detailed report listing the invoiced visits by
investigator name, accession number, date and visit name. Payment is due within
thirty (30) days of the invoice date.

Please remit payments to:
                            Quintiles Laboratories Limited
                            P.O. Box 890062
                            Charlotte, NC 28289-0062

D.8   Test and Fee Cancellation

If some or all testing for a particular visit cannot be completed due to
circumstances beyond the control of QLAB, all valid test results will be
reported and the total visit fee will remain in effect. Examples of
circumstances which can result in billable test cancellations would be: (1)
failure to include a specimen required to complete testing for the visit, (2)
specimen handling prior to courier pickup which does not meet written guidelines
established by the laboratory and (3) provision of a QNS specimen for which all
requested testing cannot be completed.

D.9   Clinical Trial Reconciliation

When The Sponsor informs QLAB in writing of the completion or cancellation of
the clinical trial, reconciliation will be conducted. This accounting will
reconcile any outstanding clinical trial-specific project initiation expenses,
scheduled or unscheduled visit fees and unsalvageable specimen collection
materials at the investigator sites. A credit or debit invoice will be issued.

                                      -18-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

D.10  Cancellation of the Clinical Trial

Upon receiving written notification of early cancellation of the clinical trial,
QLAB will provide The Sponsor with an accounting of all clinical trial-specific
project initiation expenses, scheduled and unscheduled visit fees and
unsalvageable specimen collection materials at the investigator sites. QLAB will
charge * of the PSB as a cancellation fee. If the value of efforts extended and
supplies shipped exceeds * of the total PSB, an invoice will be presented for
those fees.

D.11  Approval of Fee and Period in Force

The provisional fee schedule will expire 60 days from the date of this
Confirmation of Central Laboratory Services. Upon receiving verbal approval from
The Sponsor, QLAB will implement project initiation activities as outlined
previously in Sections A.2 and D.6. If there is a substantive change in the
expected number of investigators, number or schedule of visits, testing
requirements, anticipated commencement date, length of project or overall
protocol specific database design, QLAB will revise the Provisional Services
Budget to reflect the increase or decrease in the scope of work. Otherwise, the
fees will remain in effect for 12 months from the date study kits were first
forwarded to investigator sites. QLAB fee schedule will be subject to review on
an annual basis and will be increased for the next 12 month period based upon
the average percent change in the US Consumer Price Index over the preceding 12
month period. In the unforeseen event of governmentally mandated changes or
transportation industry regulation changes which require significant changes in
the conduct of the clinical laboratory industry, QLAB will contact The Sponsor
if there will be any cost impact on the study in progress. Additionally, if QLAB
courier fees increase 10% or more, or a fuel surcharge is imposed on QLAB for
courier services, The Sponsor will be notified immediately of the cost impact on
the study in progress.

D.12  Currency Exchange

The currency to be used to invoice and for payment is set forth in this
Provisional Services Budget attached hereto as Exhibit C (the "PSB"). If QLAB is
to perform services whereby it earns fees or incurs expenses that exceed * U.S.
dollars in a currency(ies) differing from the invoice and payment currency
(hereafter, "foreign currency(ies)"), the initial foreign currency exchange
rates used as a basis for calculating the PSB (the "PSB Rates") shall be stated
in the PSB. For each monthly invoice prepared by QLAB, QLAB will obtain the
applicable foreign currency exchange spot rates published in the Wall Street
Journal {or the Financial Times for European-based Projects} on the last
business Friday of the month to which the invoice relates (the "Current Rates").
FOR MILESTONE-BASED INVOICES, THE CURRENT RATES SHALL BE THE AVERAGE OF SUCH
FOREIGN CURRENCY EXCHANGE SPOT RATES FOR THE LAST BUSINESS FRIDAY OF EACH MONTH
BETWEEN MILESTONE INVOICES. If the Current Rates differ from the PSB Rates, a
currency adjustment will be calculated. The currency adjustment will be
calculated as the difference between the amount to be invoiced at the Current
Rates and the amount to be invoiced at the PSB Rates. If the amount to be
invoiced at the Current Rates exceeds or is less than the amount to be invoiced
at the PSB Rates, QLAB will reflect

                                      -19-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

a debit or credit adjustment, as appropriate to the monthly invoice. The PSB
will state for each currency its percentage of the total fees (and expenses, if
applicable), after its conversion into the invoice and payment currency, which
will be applied to all invoices. If a currency referenced within the PSB is
replaced by the Euro or otherwise ceases to become legal tender, the applicable
replacement currency will be substituted for such currency for purposes of this
provision at an established conversion rate.

                                      -20-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

                    ACKNOWLEDGED, ACCEPTED AND AGREED TO BY:

/s/ S. TIM DERRINGTON                             November 14, 2001
------------------------------------              --------------------------
S. Tim Derrington                                 Date
Chief Operating Officer
Quintiles Laboratories Worldwide

Authorized Representative of Northwest Biotherapeutics, Inc.:

Chris DeLuca
--------------------------------------------------------------------------------
(Type or print name)

Director of Clinical Operations
--------------------------------------------------------------------------------
(Type or print title)

/s/ CHRIS DELUCA                                           11/21/01
------------------------------------              --------------------------
Signature                                         Date

                                      -21-
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

LABORATORY EVENTS SCHEDULE                       EXHIBIT A
VERSION 09                                       START DATE:  MID SEPTEMBER 2001
NORTHWEST BIOTHERAPEUTICS, INC.
PROTOCOL:   DC3-HRPC - DOUBLE-BLIND, PLACEBO-CONTROLLED
INDICATION: PROSTATE CANCER                      PROJECT CODE: AP1215

            ENROLLMENT PERIOD: * MONTHS          PATIENT DURATION: 36 MONTHS

CENTERS: 25 - UNITED STATES
<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
                                          SCREEN BASELINE TIME WK  WK   WK   WK   WK   WK   WK   WK   WK   18   24   30   36  RETEST
NO. OF PATIENTS*                                            0   4   8   12   16   20   24   38   42   52   MO   MO   MO   MO    AS
                                                                *   *    *    *    *    *    *    *    *    *    *    *    *  NEEDED
------------------------------------------------------------------------------------------------------------------------------------
<S>                                       <C>    <C>      <C>  <C> <C>  <C>  <C>  <C>  <C>  <C>  <C>  <C>  <C>  <C>  <C>  <C> <C>
CHEMISTRY W/ 16 CONSTITUENTS                x       x       x   x   x    x         x         x         x    x    x    x    x     -
HAEMATOLOGY W/ DIFFERENTIAL &
 PLATELET COUNT                             x       x       x   x   x    x         x         x         x    x    x    x    x     -
URINALYSIS W/ MICROSCOPIC                   x                                                          x                         -
TESTOSTERONE, TOTAL                         x                                                          x                         -
PROSTATE SURFACE ANTIGEN (PSA)              x       x       x            x         x         x         x    x    x    x    x     -
PROSTATIC ACID PHOSPHATASE (PAP)            x       x       x            x         x         x         x    x    x    x    x     -
ANTI-NUCLEAR ANTIBODIES TITER (ANA)         x       x       x   x   x    x         x         x         x    x    x    x    x     -
ANTI-NUCLEAR ANTIBODIES PATTERN (ANA)       #       #       #   #   #    #         #         #         #    #    #    #    #     -
RHEUMATOID FACTOR                           x       x       x   x   x    x         x         x         x    x    x    x    x     -
HEPATITIS B SURFACE ANTIGEN (HBSAG)         x                                                                                    -
HEPATITIS B CORE TOTAL ANTIBODY
 (ANTI-HBC)                                 x                                                                                    -
HIV 1 / 2 EIA SCREEN                        x                                                                                    -
ANTI-HEPATITIS C ANTIBODY (ANTI-HCV)        x                                                                                    -
RAPID PLASMA REAGIN (RPR)                   x                                                                                    -
HTLV-I / II IGG, AB                         x                                                                                    -
HIV-1 FREE ANTIGEN                          x                                                                                    -
SPECIMEN COLLECTION & TESTING MATERIALS:
 ERYTHROCYTE SEDIMENTATION RATE (ESR)(a)    x       x       x   x   x    x         x         x         x    x    x    x    x
SPECIMEN COLLECTION MATERIALS: *                    x               x    x    x    x    x    x    x    x    x    x    x    x
SPECIMEN COLLECTION MATERIALS: *                    x               x    x    x    x    x    x    x    x    x    x    x    x
                                                   (10)            (7)  (7)  (7)  (7)  (7)  (7)  (7)  (7)  (7)  (7)  (7)  (7)
</TABLE>

KEY:   x Scheduled    - Unscheduled    # If needed

(a) Quintiles Laboratories will provide the centers with the testing
    kits/materials for consistency in methodology of on-site analysis
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

LABORATORY EVENTS SCHEDULE                      EXHIBIT A
VERSION 09                                      START DATE:   MID SEPTEMBER 2001
NORTHWEST BIOTHERAPEUTICS, INC.
PROTOCOL: DC3-HRPC - OPEN LABEL
INDICATION: PROSTATE CANCER                     PROJECT CODE: AP1239

            ENROLLMENT PERIOD: * MONTHS         PATIENT DURATION: 36 MONTHS

CENTERS:  25 - UNITED STATES
<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
                                                BASELINE TIME WK  WK   WK   WK   WK   WK   WK   WK   WK   18   24   30   36  RETEST
NO. OF PATIENTS*                                           0   4   8   12   16   20   24   38   42   52   MO   MO   MO   MO    AS
                                                               *   *    *    *    *    *    *    *    *    *    *    *    *  NEEDED
-----------------------------------------------------------------------------------------------------------------------------------
<S>                                             <C>      <C>  <C> <C>  <C>  <C>  <C>  <C>  <C>  <C>  <C>  <C>  <C>  <C>  <C> <C>
CHEMISTRY W/ 16 CONSTITUENTS                     x         x   x   x    x         x         x         x    x    x    x    x    -
HAEMATOLOGY W/ DIFFERENTIAL & PLATELET COUNT     x         x   x   x    x         x         x         x    x    x    x    x    -
URINALYSIS W/ MICROSCOPIC                                                                             x                        -
TESTOSTERONE, TOTAL                                                                                   x                        -
PROSTATE SURFACE ANTIGEN (PSA)                   x         x            x         x         x         x    x    x    x    x    -
PROSTATIC ACID PHOSPHATASE (PAP)                 x         x            x         x         x         x    x    x    x    x    -
ANTI-NUCLEAR ANTIBODIES TITER (ANA)              x         x   x   x    x         x         x         x    x    x    x    x    -
ANTI-NUCLEAR ANTIBODIES PATTERN (ANA)            #         #   #   #    #         #         #         #    #    #    #    #    -
RHEUMATOID FACTOR                                x         x   x   x    x         x         x         x    x    x    x    x    -
SPECIMEN COLLECTION & TESTING MATERIALS:
  ERYTHROCYTE SEDIMENTATION RATE (ESR)(a)        x         x   x   x    x         x         x         x    x    x    x    x
SPECIMEN COLLECTION MATERIALS: *                 x                 x    x    x    x    x    x    x    x    x    x    x    x
SPECIMEN COLLECTION MATERIALS: *                 x                 x    x    x    x    x    x    x    x    x    x    x    x
                                                (10)              (7)  (7)  (7)  (7)  (7)  (7)  (7)  (7)  (7)  (7)  (7)  (7)
</TABLE>

KEY:    x  Scheduled    -  Unscheduled    #  If needed

(a) Quintiles Laboratories will provide the centers with the testing
    kits/materials for consistency in methodology of on-site analysis.
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

                                    EXHIBIT B
                             LABORATORY REQUIREMENTS
                                   VERSION 09
                         NORTHWEST BIOTHERAPEUTICS, INC.
                               PROTOCOL: DC3-HRPC
                           INDICATION: PROSTATE CANCER

CHEMISTRY                             URINALYSIS(1)
Sodium                                PH
Potassium                             Specific Gravity
Chloride                              Glucose
Bicarbonate                           Protein
BUN                                   Ketones
Creatinine                            Blood
Magnesium                             Microscopic
Calcium                               METHOD: BAYER MULTISTIX/MANUAL MICROSCOPY
Phosphorus
Glucose                               SPECIAL CHEMISTRY
ALT (SGPT)                            Testosterone, Total(2a)
AST (SGOT)                            METHOD: BAYER CHEMILUMINESCENCE
Total Bilirubin                       Prostate Specific Antigen (PSA)(2a)
Albumin                               METHOD:  ABBOTT MEIA
Alkaline Phosphatase                  Prostatic Acid Phosphatase (PAP)(2b)
LDH                                   METHOD: ICMA
METHOD: ROCHE BMD
                                      IMMUNOLOGY
HAEMATOLOGY(1)                        Anti-Nuclear Antibodies Titer (ANA)(2a)
Haemoglobin                           Anti-Nuclear Antibodies Pattern (ANA)(2a)
Haematocrit                           METHOD: IFA
MCV                                   Rheumatoid Factor(2a)
MCH                                   METHOD: ROCHE TINAQUANT
MCHC
RBC
WBC
Platelet Count
RBC Morphology
Differential
RDW
METHOD: BECKMAN/COULTER/MANUAL MICROSCOPY

PLEASE NOTE: Quintiles Laboratories will provide the centers with all the
materials necessary for specimen collection, temporary storage and overnight
shipping of samples. Services assume that all samples will ship ambient on the
day of collection, unless otherwise noted.

(1) Quintiles Laboratories assumes standard test panels. Customization of
testing may result in budget changes.

(2) The centers will collect the specimens and store at - 20(degree)C or colder.
On the day of collection at the Screen Visit and at the Baseline Visit and
monthly thereafter, the centers will ship the frozen samples on dry ice (to be
provided BY the centers) to Quintiles Laboratories.

      (2a) Upon receipt, Quintiles Laboratories will analyze the samples and
      issue a laboratory report.

      (2b) Upon receipt Quintiles Laboratories will repackage the samples and
      forward to Specialty Laboratories for analysis. The results will be
      entered into the Quintiles Laboratories protocol specific database and
      reports will be issued to the centers.
<PAGE>
* AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

                                    EXHIBIT B
                             LABORATORY REQUIREMENTS
                                   VERSION 09
                         NORTHWEST BIOTHERAPEUTICS, INC.
                               PROTOCOL: DC3-HRPC
                           INDICATION: PROSTATE CANCER

<TABLE>
<S>                                           <C>
VIROLOGY                                      SPECIMEN COLLECTION & TESTING MATERIALS
Hepatitis B Surface Antigen (HBsAg)           Erythrocyte Sedimentation Rate (ESR)(4)
Hepatitis B Core Total Antibody (Anti-HBc)
HIV 1/2 EIA Screen                            SPECIMEN COLLECTION MATERIALS(5)
Hepatitis C Antibody (Anti-HCV)               *
METHOD: ABBOTT EIA
Rapid Plasma Reagin (RPR)
METHOD:  BECTON-DICKSON MACRO-VUE
HTLV-I / II IgG, Ab(3)
METHOD:  EIA
HIV-1 Free Antigen(3)
METHOD: EIA/IB
</TABLE>

(3) Upon receipt Quintiles Laboratories will forward the ambient samples to
Specialty Laboratories for analysis. The results will be entered into the
Quintiles Laboratories protocol specific database and reports will be issued to
the centers.

(4) Quintiles laboratories will provide the centers with the testing
kits/materials for consistency in methodology of on-site analysis.

(5) *
<PAGE>
*AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

PROVISIONAL SERVICES BUDGET - LINE ITEM - NORTH AMERICA                EXHIBIT C
VERSION: 09
NORTHWEST BIOTHERAPEUTICS, INC.
PROTOCOL: DC3-HRPC - DOUBLE-BLINDED, PLACEBO-CONTROLLED
INDICATION: PROSTATE CANCER

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------
                                                                                 NO. OF                        EXTENDED
                   SERVICE OR TEST DESCRIPTION                              PATIENT VISITS*       FEE*           FEE*
-----------------------------------------------------------------------------------------------------------------------
<S>                                                                         <C>                   <C>          <C>
ADMINISTRATIVE / DATABASE
SET UP & PROJECT MANAGEMENT (fees based on a project
duration of * for enrollment; 36 months patient duration.
Extensions to the duration of the project may result in additional fees).                                         *

DATABASE DEVELOPMENT                                                                                              *

DATABASE TRANSMISSIONS & ROUTINE MAINTENANCE                                       *               *              *

ANALYTICAL TESTING

CHEMISTRY W/ 16 CONSTITUENTS                                                       *               *              *

HAEMATOLOGY W/ DIFFERENTIAL & PLATELET COUNT                                       *               *              *

URINALYSIS W/ MICROSCOPIC                                                          *               *              *

TESTOSTERONE, TOTAL                                                                *               *              *

PROSTATE SURFACE ANTIGEN (PSA)                                                     *               *              *

PROSTATIC ACID PHOSPHATASE (PAP): SPECIALTY LAB                                    *               *              *

ANTI-NUCLEAR ANTIBODIES TITER (ANA)                                                *               *              *

ANTI-NUCLEAR ANTIBODIES PATTERN (ANA)                                              *               *              *

RHEUMATOID FACTOR                                                                  *               *              *

HEPATITIS SCREEN PANEL  (HBsAg and ANTI-HCV)                                       *               *              *

HEPATITIS B CORE TOTAL ANTIBODY (ANTI-Hbc)                                         *               *              *

HIV 1/2 EIA SCREEN                                                                 *               *              *

RAPID PLASMA REAGIN (RPR)                                                          *               *              *

HTLV-I/II IgG, Ab:  SPECIALTY LAB                                                  *               *              *

HIV-I FREE ANTIGEN:  SPECIALTY LAB                                                 *               *              *

REPORTING

FAX REPORT TO INVESTIGATOR - UNITED STATES DAILY                                   *               *              *

FAX REPORT TO INVESTIGATOR - UNITED STATES MONTHLY                                 *               *              *

FAX REPORT TO INVESTIGATOR - SPECIALTY LAB REPORT                                  *               *              *

QNET(TM) LABORATORY REPORTING SOFTWARE                                             *               *              *

KIT CONSTRUCTION & SUPPLIES

KIT TRANSPORTATION MANAGEMENT FEE - UNITED STATES                                  *               *              *

AMBIENT KITS                                                                       *               *              *
</TABLE>

<PAGE>

*AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

<TABLE>
<S>                                                                         <C>                   <C>        <C>

*                                                                                  *               *              *

*                                                                                  *               *              *

NON-INFECTIOUS FROZEN SHIPPER                                                      *               *              *

ERYTHROCYTE SEDIMENTATION RATE (ESR) KITS                                          *               *              *

TRANSPORTATION - UNITED STATES

BULK DISTRIBUTION - AMBIENT QKITS                                                  *               *              *

*                                                                                  *               *              *

*                                                                                  *               *              *

BULK DISTRIBUTION - NON-INFECTIOUS FROZEN SHIPPER                                  *               *              *

INBOUND - AMBIENT QKITS                                                            *               *              *

*                                                                                  *               *              *

INBOUND - NON-INFECTIOUS FROZEN SHIPPER                                            *               *              *

                                           TOTAL PROVISIONAL SERVICES BUDGET                                 $1,305,179.01
</TABLE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------
                                                                           NO. OF PATIENT                       EXTENDED
                    DESCRIPTION                                                VISITS*            FEE*            FEE*
------------------------------------------------------------------------------------------------------------------------
<S>                                                                        <C>                    <C>         <C>
ADMINISTRATIVE / DATABASE

Total for services outlined on line item budget                                                                    *

VISIT FEES -- UNITED STATES (INCLUDES ANALYTICAL AND REPORTING)

SCREEN VISIT                                                                      *                *               *

BASELINE VISIT                                                                    *                *               *

TIME 0 VISIT, WEEKS 12, 20, 38, MONTHS 18, 24, 30 AND 36 VISITS                   *                *               *

WEEKS 4 AND 8 VISITS                                                              *                *               *

WEEK 52 VISIT                                                                     *                *               *

RETEST VISIT                                                                      *                *               *

KIT SUPPLY VISIT FEES -- UNITED STATES (INCLUDES KIT SUPPLIES
AND KIT TRANSPORTATION MANAGEMENT FEE)

SCREEN, BASELINE, TIME 0, WEEKS 4, 8, 12, 20, 38, 52,
MONTHS 18, 24, 30 and 36 VISITS KIT                                               *                *               *

*                                                                                 *                *               *

*                                                                                 *                *               *

NON-INFECTIOUS FROZEN SHIPPER                                                     *                *               *

RETEST VISIT KIT                                                                  *                *               *
</TABLE>

<PAGE>

*AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

<TABLE>
<S>                                                                        <C>                    <C>     <C>
TRANSPORTATION ESTIMATE FOR NORTH AMERICA (TOTAL FROM
SERVICES OUTLINED ON THE LINE ITEM BUDGET)                                                                           *

                                              PROVISIONAL SERVICES BUDGET                                 $1,305,179.0
</TABLE>

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------------------
                                                                            NO. OF PATIENT                    EXTENDED
                   SERVICE OR TEST DESCRIPTION                                  VISITS*            FEE*         FEE*
----------------------------------------------------------------------------------------------------------------------
<S>                                                                         <C>                    <C>      <C>
ADMINISTRATIVE / DATABASE

SET UP & PROJECT MANAGEMENT (fees based on a project
duration of * for enrollment; 36 months patient duration.                                                         *
Extensions to the duration of the project may result in additional fees.

DATABASE DEVELOPMENT                                                                                              *

ANALYTICAL TESTING

CHEMISTRY W/ 16 CONSTITUENTS                                                       *                *             *

HAEMATOLOGY W/ DIFFERENTIAL & PLATELET COUNT                                       *                *             *

URINALYSIS W/ MICROSCOPIC                                                          *                *             *

TESTOSTERONE, TOTAL                                                                *                *             *

PROSTATE SURFACE ANTIGEN (PSA)                                                     *                *             *

PROSTATIC ACID PHOSPHATASE (PAP):  Specialty Lab                                   *                *             *

ANTI-NUCLEAR ANTIBODIES TITER (ANA)                                                *                *             *

ANTI-NUCLEAR ANTIBODIES PATTERN (ANA)                                              *                *             *

RHEUMATOID FACTOR                                                                  *                *             *

REPORTING

FAX REPORT TO INVESTIGATOR -- UNITED STATES DAILY                                  *                *             *

FAX REPORT TO INVESTIGATOR -- UNITED STATES WEEKLY                                 *                *             *

QNET(TM) LABORATORY REPORTING SOFTWARE                                             *                *             *

KIT CONSTRUCTION & SUPPLIES

KIT TRANSPORTATION MANAGEMENT FEE -- UNITED STATES                                 *                *             *

AMBIENT QKITS                                                                      *                *             *

*                                                                                  *                *             *

*                                                                                  *                *             *

NON-INFECTIOUS FROZEN SHIPPER                                                      *                *             *

ERYTHROCYTE SEDIMENTATION RATE (ESR) KITS                                          *                *             *

TRANSPORTATION -- UNITED STATES

BULK DISTRIBUTION -- AMBIENT QKITS                                                 *                *             *
</TABLE>

<PAGE>

*AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 7, 2001
INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
AND HAS BEEN FILED SEPARATELY WITH THE SEC.

<TABLE>
<S>                                                                         <C>                    <C>  <C>
*                                                                                  *                *             *

*                                                                                  *                *             *

BULK DISTRIBUTION -- NON-INFECTIOUS FROZEN SHIPPER                                 *                *             *

INBOUND -- AMBIENT QKITS                                                           *                *             *

*                                                                                  *                *             *

INBOUND -- NON-INFECTIOUS FROZEN SHIPPER                                           *                *             *

                                    TOTAL PROVISIONAL SERVICES BUDGET                                   $315,644.95
</TABLE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------
                                                                            NO. OF PATIENT                      EXTENDED
                        DESCRIPTION                                             VISITS*          FEE*             FEE*
------------------------------------------------------------------------------------------------------------------------
<S>                                                                         <C>                  <C>      <C>
ADMINISTRATIVE / DATABASE

Total for services outlined on line item budge                                                                      *

VISIT FEES -- UNITED STATES (INCLUDES ANALYTICAL AND REPORTING)

BASELINE VISIT                                                                     *              *                 *

TIME 0 VISIT, WEEKS 12, 20, 38, MONTHS 18, 24, 30 AND 36 VISITS                    *              *                 *

WEEKS 4 AND 8 VISITS                                                               *              *                 *

WEEK 52 VISIT                                                                      *              *                 *

RETEST VISIT                                                                       *              *                 *

KIT SUPPLY VISIT FEES -- UNITED STATES (INCLUDES KIT SUPPLIES AND
KIT TRANSPORTATION MANAGEMENT FEE)

SCREEN, BASELINE, TIME 0, WEEKS 4, 8, 12, 20, 38, 52, MONTHS 18,
24, 30 AND 36 VISITS KIT                                                           *              *                 *

*                                                                                  *              *                 *

*                                                                                  *              *                 *

NON-INFECTIOUS FROZEN SHIPPER                                                      *              *                 *

RETEST VISIT KIT                                                                   *              *                 *

TRANSPORTATION ESTIMATE FOR NORTH AMERICA (TOTAL FROM SERVICES
OUTLINED ON THE LINE ITEM BUDGET)                                                                                   *

                                              PROVISIONAL SERVICES BUDGET                                 $315,644.95

</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}]]